Outcome of myeloma patients with COVID-19 on active lenalidomide-based therapy: Does lenalidomide protect from severe COVID-19?

Patients with haematological cancers and concurrent coronavirus disease 2019 (COVID-19) reportedlyhave poor outcomes as indicated by high hospitalisation rates, high case fatality rates in mechanically ventilated patients, and a high mortality rate of 10% [1–3]. A recent small study reported a high...

Full description

Autores:

Tipo de recurso:

Article of investigation

Fecha de publicación:

2020

Institución:

Universidad de Bogotá Jorge Tadeo Lozano

Repositorio:

Expeditio: repositorio UTadeo

Idioma:

eng

OAI Identifier:

oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/14298

Acceso en línea:

https://doi.org/10.1016/j.hemonc.2020.08.002
http://hdl.handle.net/20.500.12010/14298

Palabra clave:

COVID-19
Lenalidomide-based therapy
Myeloma patients
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus

Rights

License

Abierto (Texto Completo)